Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.

Xu Y, Taylor P, Andrade J, Ueberheide B, Shuch B, Glazer PM, Bindra RS, Moran MF, Linehan WM, Neel BG.

Cancer Res. 2018 Oct 8. pii: canres.0901.2018. doi: 10.1158/0008-5472.CAN-18-0901. [Epub ahead of print]

PMID:
30297534
2.

Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM.

Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.

PMID:
30013182
3.

In utero nanoparticle delivery for site-specific genome editing.

Ricciardi AS, Bahal R, Farrelly JS, Quijano E, Bianchi AH, Luks VL, Putman R, López-Giráldez F, Coşkun S, Song E, Liu Y, Hsieh WC, Ly DH, Stitelman DH, Glazer PM, Saltzman WM.

Nat Commun. 2018 Jun 26;9(1):2481. doi: 10.1038/s41467-018-04894-2.

4.

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.

Lu Y, Liu Y, Oeck S, Glazer PM.

Mol Cancer Res. 2018 Oct;16(10):1458-1469. doi: 10.1158/1541-7786.MCR-17-0637. Epub 2018 Jun 22.

5.

PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF.

Sulkowski PL, Scanlon SE, Oeck S, Glazer PM.

Mol Cancer Res. 2018 Aug;16(8):1241-1254. doi: 10.1158/1541-7786.MCR-17-0581. Epub 2018 May 8.

PMID:
29739874
6.

Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing.

Ricciardi AS, Quijano E, Putman R, Saltzman WM, Glazer PM.

Molecules. 2018 Mar 11;23(3). pii: E632. doi: 10.3390/molecules23030632. Review.

7.

The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.

Kim H, Lin Q, Glazer PM, Yun Z.

Breast Cancer Res. 2018 Mar 6;20(1):16. doi: 10.1186/s13058-018-0944-8.

8.

Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma.

Scanlon SE, Hegan DC, Sulkowski PL, Glazer PM.

Oncotarget. 2017 Dec 19;9(4):4647-4660. doi: 10.18632/oncotarget.23470. eCollection 2018 Jan 12.

9.

Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities.

Quijano E, Bahal R, Ricciardi A, Saltzman WM, Glazer PM.

Yale J Biol Med. 2017 Dec 19;90(4):583-598. eCollection 2017 Dec. Review.

10.

Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy.

Gupta A, Quijano E, Liu Y, Bahal R, Scanlon SE, Song E, Hsieh WC, Braddock DE, Ly DH, Saltzman WM, Glazer PM.

Mol Ther Nucleic Acids. 2017 Dec 15;9:111-119. doi: 10.1016/j.omtn.2017.09.001. Epub 2017 Sep 12.

11.

A cell-penetrating antibody inhibits human RAD51 via direct binding.

Turchick A, Hegan DC, Jensen RB, Glazer PM.

Nucleic Acids Res. 2017 Nov 16;45(20):11782-11799. doi: 10.1093/nar/gkx871.

12.

Nickel induces transcriptional down-regulation of DNA repair pathways in tumorigenic and non-tumorigenic lung cells.

Scanlon SE, Scanlon CD, Hegan DC, Sulkowski PL, Glazer PM.

Carcinogenesis. 2017 Jun 1;38(6):627-637. doi: 10.1093/carcin/bgx038.

13.

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.

Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS.

Sci Transl Med. 2017 Feb 1;9(375). pii: eaal2463. doi: 10.1126/scitranslmed.aal2463.

14.

DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.

Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB.

Mol Cancer Res. 2017 Mar;15(3):269-280. doi: 10.1158/1541-7786.MCR-16-0227-T. Epub 2017 Jan 10.

15.

In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery.

Bahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM.

Nat Commun. 2016 Oct 26;7:13304. doi: 10.1038/ncomms13304.

16.

miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair.

Czochor JR, Sulkowski P, Glazer PM.

Mol Cancer Res. 2016 Apr;14(4):363-73. doi: 10.1158/1541-7786.MCR-15-0399. Epub 2016 Feb 5.

17.

Nanotechnology for delivery of peptide nucleic acids (PNAs).

Gupta A, Bahal R, Gupta M, Glazer PM, Saltzman WM.

J Control Release. 2016 Oct 28;240:302-311. doi: 10.1016/j.jconrel.2016.01.005. Epub 2016 Jan 8. Review.

18.

DNA-dependent targeting of cell nuclei by a lupus autoantibody.

Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE.

Sci Rep. 2015 Jul 9;5:12022. doi: 10.1038/srep12022.

19.

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.

Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM.

Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26.

20.

Tumor suppressor p53 stole the AKT in hypoxia.

Yun Z, Glazer PM.

J Clin Invest. 2015 Jun;125(6):2264-6. doi: 10.1172/JCI82058. Epub 2015 May 11.

21.

Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.

Scanlon SE, Glazer PM.

DNA Repair (Amst). 2015 Aug;32:180-9. doi: 10.1016/j.dnarep.2015.04.030. Epub 2015 May 1. Review.

22.

Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium.

McNeer NA, Anandalingam K, Fields RJ, Caputo C, Kopic S, Gupta A, Quijano E, Polikoff L, Kong Y, Bahal R, Geibel JP, Glazer PM, Saltzman WM, Egan ME.

Nat Commun. 2015 Apr 27;6:6952. doi: 10.1038/ncomms7952.

23.

Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines.

Colis LC, Hegan DC, Kaneko M, Glazer PM, Herzon SB.

J Am Chem Soc. 2015 May 6;137(17):5741-7. doi: 10.1021/ja513117p. Epub 2015 Apr 22.

24.

LKB1 preserves genome integrity by stimulating BRCA1 expression.

Gupta R, Liu AY, Glazer PM, Wajapeyee N.

Nucleic Acids Res. 2015 Jan;43(1):259-71. doi: 10.1093/nar/gku1294. Epub 2014 Dec 8.

25.

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ.

Nature. 2015 Feb 5;518(7537):107-10. doi: 10.1038/nature13905. Epub 2014 Nov 17.

26.

Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules.

Reza F, Glazer PM.

Methods Mol Biol. 2015;1239:39-73. doi: 10.1007/978-1-4939-1862-1_4.

PMID:
25408401
27.

Single-stranded γPNAs for in vivo site-specific genome editing via Watson-Crick recognition.

Bahal R, Quijano E, McNeer NA, Liu Y, Bhunia DC, Lopez-Giraldez F, Fields RJ, Saltzman WM, Ly DH, Glazer PM.

Curr Gene Ther. 2014;14(5):331-42.

28.

Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung.

Fields RJ, Quijano E, McNeer NA, Caputo C, Bahal R, Anandalingam K, Egan ME, Glazer PM, Saltzman WM.

Adv Healthc Mater. 2015 Feb 18;4(3):361-6. doi: 10.1002/adhm.201400355. Epub 2014 Aug 25.

29.

Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1.

Lu Y, Wajapeyee N, Turker MS, Glazer PM.

Cell Rep. 2014 Jul 24;8(2):501-13. doi: 10.1016/j.celrep.2014.06.035. Epub 2014 Jul 17.

30.

Targeted genome modification via triple helix formation.

Ricciardi AS, McNeer NA, Anandalingam KK, Saltzman WM, Glazer PM.

Methods Mol Biol. 2014;1176:89-106. doi: 10.1007/978-1-4939-0992-6_8.

31.

HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.

Zhang M, Xiang S, Joo HY, Wang L, Williams KA, Liu W, Hu C, Tong D, Haakenson J, Wang C, Zhang S, Pavlovicz RE, Jones A, Schmidt KH, Tang J, Dong H, Shan B, Fang B, Radhakrishnan R, Glazer PM, Matthias P, Koomen J, Seto E, Bepler G, Nicosia SV, Chen J, Li C, Gu L, Li GM, Bai W, Wang H, Zhang X.

Mol Cell. 2014 Jul 3;55(1):31-46. doi: 10.1016/j.molcel.2014.04.028. Epub 2014 May 29.

32.

The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA.

Colis LC, Woo CM, Hegan DC, Li Z, Glazer PM, Herzon SB.

Nat Chem. 2014 Jun;6(6):504-10. doi: 10.1038/nchem.1944. Epub 2014 May 11.

33.

Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.

Scanlon SE, Glazer PM.

Mol Cancer Res. 2014 Jul;12(7):1016-28. doi: 10.1158/1541-7786.MCR-13-0628. Epub 2014 Mar 31.

34.

Triplex-mediated genome targeting and editing.

Reza F, Glazer PM.

Methods Mol Biol. 2014;1114:115-42. doi: 10.1007/978-1-62703-761-7_8.

PMID:
24557900
35.

Introduction.

Sweasy JB, Glazer PM.

Yale J Biol Med. 2013 Dec;86(4):441-2. No abstract available.

36.

Interplay between DNA repair and inflammation, and the link to cancer.

Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, Sweasy JB.

Crit Rev Biochem Mol Biol. 2014 Mar-Apr;49(2):116-39. doi: 10.3109/10409238.2013.875514. Epub 2014 Jan 13. Review.

37.

Hypoxia and DNA repair.

Glazer PM, Hegan DC, Lu Y, Czochor J, Scanlon SE.

Yale J Biol Med. 2013 Dec 13;86(4):443-51.

38.

Peptide nucleic acid-mediated recombination for targeted genomic repair and modification.

Schleifman EB, Glazer PM.

Methods Mol Biol. 2014;1050:207-22. doi: 10.1007/978-1-62703-553-8_17.

PMID:
24297362
39.

Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice.

Schleifman EB, McNeer NA, Jackson A, Yamtich J, Brehm MA, Shultz LD, Greiner DL, Kumar P, Saltzman WM, Glazer PM.

Mol Ther Nucleic Acids. 2013 Nov 19;2:e135. doi: 10.1038/mtna.2013.59.

40.

microRNAs in cancer cell response to ionizing radiation.

Czochor JR, Glazer PM.

Antioxid Redox Signal. 2014 Jul 10;21(2):293-312. doi: 10.1089/ars.2013.5718. Epub 2014 Feb 4. Review.

41.

Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5.

Bahal R, McNeer NA, Ly DH, Saltzman WM, Glazer PM.

Artif DNA PNA XNA. 2013 Apr-Jun;4(2):49-57.

42.

Radiation sensitivity and sensitization in melanoma.

Shahbazian D, Bindra RS, Kluger HM, Glazer PM.

Pigment Cell Melanoma Res. 2013 Nov;26(6):928-30. doi: 10.1111/pcmr.12147. Epub 2013 Aug 12. No abstract available.

43.

Triplex-forming peptide nucleic acids induce heritable elevations in gamma-globin expression in hematopoietic progenitor cells.

Chin JY, Reza F, Glazer PM.

Mol Ther. 2013 Mar;21(3):580-7. doi: 10.1038/mt.2012.262. Epub 2013 Jan 22.

44.

Targeting cancer with a lupus autoantibody.

Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM.

Sci Transl Med. 2012 Oct 24;4(157):157ra142. doi: 10.1126/scitranslmed.3004385.

45.

Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo.

McNeer NA, Schleifman EB, Cuthbert A, Brehm M, Jackson A, Cheng C, Anandalingam K, Kumar P, Shultz LD, Greiner DL, Mark Saltzman W, Glazer PM.

Gene Ther. 2013 Jun;20(6):658-69. doi: 10.1038/gt.2012.82. Epub 2012 Oct 18.

46.

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.

Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L.

Breast Cancer Res Treat. 2012 Nov;136(1):67-75. doi: 10.1007/s10549-012-2232-0. Epub 2012 Sep 14.

PMID:
22976806
47.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP.

Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.

48.

Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Akintujoye OM, Glazer PM, Sartorelli AC.

Int J Radiat Biol. 2012 Mar;88(3):277-85. doi: 10.3109/09553002.2012.638359. Epub 2011 Dec 20.

49.

Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.

Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ.

Cancer Biol Ther. 2011 Nov 15;12(10):908-14. doi: 10.4161/cbt.12.10.17681. Epub 2011 Nov 15.

50.

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.

Schleifman EB, Bindra R, Leif J, del Campo J, Rogers FA, Uchil P, Kutsch O, Shultz LD, Kumar P, Greiner DL, Glazer PM.

Chem Biol. 2011 Sep 23;18(9):1189-98. doi: 10.1016/j.chembiol.2011.07.010.

Supplemental Content

Loading ...
Support Center